enGene Holdings Inc. Board of Directors

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). The company is based in Montreal, Canada.

Mr. John C. Brown D.Sc., FRSC, Ph.D.

Mr. John C. Brown D.Sc., FRSC, Ph.D.

Co-Founder and Member of Scientific Advisory Board

Dr. Anthony T. Cheung Ph.D.

Dr. Anthony T. Cheung Ph.D.

Co-Founder & Chief Scientific Officer

Dr. Alex Nichols Ph.D.

Dr. Alex Nichols Ph.D.

Chief Strategy & Operations Officer

Mr. David Ryan Daws

Mr. David Ryan Daws

CFO & Head of Business Development

Dr. Raj Pruthi F.A.C.S., M.D., M.H.A.

Dr. Raj Pruthi F.A.C.S., M.D., M.H.A.

Chief Medical Officer

Mr. Paul Erickson

Mr. Paul Erickson

Non-Executive Director

Ms. Joan Connolly

Ms. Joan Connolly

Chief Technology Officer

Mr. Ronald H. W. Cooper

Mr. Ronald H. W. Cooper

Chief Executive Officer & Director

Ms. Sharon Tan

Ms. Sharon Tan

VP of Project Management & Head of Program Management

Mr. Lee G. Giguere

Mr. Lee G. Giguere

Chief Legal Officer & Corporate Secretary

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments

Comment created.